Get the Stockscreener App
38.65
3.03%
1.135
Harmony Biosciences Holdings Inc stock is traded at $38.65, with a volume of 270.15K.
It is up +3.03% in the last 24 hours and down -8.36% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$37.51
Open:
$38.04
24h Volume:
270.15K
Relative Volume:
0.30
Market Cap:
$2.25B
Revenue:
$899.11M
Net Income/Loss:
$145.62M
P/E Ratio:
15.56
EPS:
2.4829
Net Cash Flow:
$322.54M
1W Performance:
-2.41%
1M Performance:
-8.36%
6M Performance:
+32.26%
1Y Performance:
+45.12%
1-Day Range:
$38.00
$39.00
1-Week Range:
$35.99
$40.57
52-Week Range:
$25.52
$43.49
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
38.65 | 2.25B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.14 | 95.07B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.61 | 82.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.15 | 53.40B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-23-26 | Downgrade | Truist | Buy → Hold |
| Feb-11-26 | Resumed | UBS | Neutral |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.
Why Harmony Biosciences Stock Got Mashed on Monday - The Motley Fool
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth - Investing News Network
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth - GlobeNewswire Inc.
HRMY vs. CSLLY: Which Stock Is the Better Value Option? - Zacks Investment Research
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? - Zacks Investment Research
Harmony Biosciences Holdings (NasdaqGM:HRMY) Stock Forecast & Analyst Predictions - Simply Wall Street
Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harmony Biosciences CMO sells $1.65m in shares By Investing.com - Investing.com South Africa
Harmony Biosciences CMO sells $1.65m in shares By Investing.com - Investing.com Australia
Harmony Biosciences CMO sells $1.65m in shares - Investing.com
Harmony Biosciences (HRMY) CMO exercises options and sells shares - Stock Titan
$1.5M stock sale planned by Harmony Biosciences (NASDAQ: HRMY) officer - Stock Titan
Harmony Biosciences Holdings Insider Sold Shares Worth $1,655,416, According to a Recent SEC Filing - Yahoo Finance
After preset plan trades, Harmony Biosciences (NASDAQ: HRMY) officer plans 800-share sale - Stock Titan
Harmony Biosciences Holdings, Inc.Common Stock (Nasdaq:HRMY) Price Chart - The Chronicle-Journal
Officer stock sale at Harmony Biosciences (NASDAQ: HRMY) follows earlier 10b5-1 trades - Stock Titan
(HRMY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HRMY: Pipeline expansion, BP-205 progress, and BD deals drive next phase of growth - TradingView
Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs - Benzinga
Harmony Biosciences CMO Kumar Budur Executes Stock Sales and Option Exercises in Early September 2026 - Kalkine Media
Harmony Biosciences (NASDAQ: HRMY) CMO exercises 22,954 options, sells shares under trading plan - Stock Titan
Harmony Biosciences Holdings Insider Sold Shares Worth $1,453,169, According to a Recent SEC Filing - Yahoo Finance
Harmony Biosciences (NASDAQ: HRMY) officer lines up a seven-figure stock sale - Stock Titan
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now - Eastern Progress
Harmony Biosciences stock holds near USD 41.86 - AD HOC NEWS
Harmony Biosciences (HRMY) executive to sell about $230K in stock - Stock Titan
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report? - Yahoo Finance
Harmony Biosciences to Present Encore EPX-100 Data from ARGUS Study at 16th European Epilepsy Congress - Quiver Quantitative
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress - Yahoo Finance
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com South Africa
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com Canada
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com India
Harmony Biosciences stock hits 52-week high at $42.70 - Investing.com
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones - Stock Traders Daily
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - Investing News Network
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - GlobeNewswire
HRMY Initiates Coverage On Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates Harmony Biosciences stock at Outperform - Investing.com
Wolfe Research initiates Harmony Biosciences stock at Outperform By Investing.com - Investing.com Canada
Wolfe Research initiates Harmony Biosciences stock at Outperform By Investing.com - Investing.com UK
Virtus Advisers LLC Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Stephen M. Mollichella Net Worth (2026) - GuruFocus
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harmony Biosciences Holdings Inc Stock (HRMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KUMAR BUDUR | Officer |
Sep 18 '26 |
Proposed Sale |
42.74 |
35,852 |
1,532,314 |
0 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 18 '26 |
Sale |
43.05 |
35,852 |
1,543,590 |
13,115 |
| KUMAR BUDUR | Officer |
Sep 17 '26 |
Proposed Sale |
42.21 |
800 |
33,768 |
0 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Option Exercise |
30.48 |
800 |
24,384 |
13,915 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Sale |
43.00 |
800 |
34,400 |
13,115 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 16 '26 |
Option Exercise |
30.48 |
1,800 |
54,864 |
14,915 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 16 '26 |
Sale |
43.01 |
1,800 |
77,426 |
13,115 |
| KUMAR BUDUR | Officer |
Sep 16 '26 |
Proposed Sale |
42.17 |
1,800 |
75,906 |
0 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 08 '26 |
Option Exercise |
30.49 |
22,954 |
699,942 |
36,069 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 08 '26 |
Sale |
42.96 |
28,454 |
1,222,258 |
13,115 |
3.32%
3.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):